NASDAQ:ATHA Athira Pharma (ATHA) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ATHA Stock Alerts $2.01 -0.03 (-1.47%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.00▼$2.1050-Day Range$2.04▼$4.1552-Week Range$1.33▼$4.30Volume79,001 shsAverage Volume387,328 shsMarket Capitalization$77.04 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Athira Pharma alerts: Email Address Athira Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside497.0% Upside$12.00 Price TargetShort InterestHealthy2.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.86) to ($3.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 starsMedical Sector564th out of 907 stocksBiological Products, Except Diagnostic Industry94th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingAthira Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAthira Pharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.86% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athira Pharma has recently increased by 3.13%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHA. Previous Next 1.3 News and Social Media Coverage News SentimentAthira Pharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ATHA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athira Pharma are expected to decrease in the coming year, from ($2.86) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Athira Pharma Stock (NASDAQ:ATHA)Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Read More ATHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHA Stock News HeadlinesApril 23, 2024 | finance.yahoo.comOne Athira Pharma Insider Raised Their Stake In The Previous YearApril 17, 2024 | msn.comAthira Pharma (ATHA) Price Target Increased by 7.49% to 7.57April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 15, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerApril 15, 2024 | markets.businessinsider.comAthira Pharma Appoints Javier San Martin As New Chief Medical OfficerApril 15, 2024 | globenewswire.comAthira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerApril 11, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseApril 11, 2024 | finance.yahoo.comAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 11, 2024 | globenewswire.comAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseApril 3, 2024 | globenewswire.comAthira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingMarch 20, 2024 | finance.yahoo.comAthira Pharma, Inc. (ATHA)March 8, 2024 | finance.yahoo.comAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International ConferenceMarch 8, 2024 | globenewswire.comAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International ConferenceFebruary 23, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesFebruary 22, 2024 | globenewswire.comAthira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesFebruary 8, 2024 | finance.yahoo.comAthira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)February 6, 2024 | uk.investing.comAthira Pharma Inc (ATHA)January 22, 2024 | finance.yahoo.comWith 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investorsJanuary 11, 2024 | markets.businessinsider.comAthira Pharma: A Buy Rating Backed by Promising Alzheimer’s Drug Prospects and Strong Cash PositionJanuary 10, 2024 | bizjournals.comAthira Pharma's chief medical officer retiresJanuary 8, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)January 8, 2024 | finance.yahoo.comAthira Pharma Provides 2024 Clinical Pipeline Outlook and Business UpdateJanuary 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Athira Pharma as LIFT-AD Trial Progresses with Promising Prospects and Solid Financial StandingJanuary 3, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's DiseaseJanuary 2, 2024 | msn.comAthira Pharma 10% owner Perceptive Advisors discloses purchase of 605,686 sharesDecember 25, 2023 | benzinga.comAthira Pharma Stock (NASDAQ:ATHA) Dividends: History, Yield and DatesSee More Headlines Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$19.00 Low Stock Price Target$5.00 Potential Upside/Downside+497.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.11% Return on Assets-59.90% Debt Debt-to-Equity RatioN/A Current Ratio5.37 Quick Ratio5.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book0.59Miscellaneous Outstanding Shares38,330,000Free Float31,811,000Market Cap$77.04 million OptionableOptionable Beta2.77 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Mark J. Litton M.B.A. (Age 56)Ph.D., President, CEO & Director Comp: $882.7kDr. Kevin Church Ph.D. (Age 39)Chief Scientific Officer Comp: $123.67kMs. Julie RathbunHead of Investor RelationsMr. Mark F. Worthington J.D. (Age 58)General Counsel & Corporate Secretary Comp: $503.83kMs. Samantha WillingChief People OfficerKey CompetitorsCognition TherapeuticsNASDAQ:CGTXCEL-SCINYSE:CVMPassage BioNASDAQ:PASGGritstone bioNASDAQ:GRTSPrecision BioSciencesNASDAQ:DTILView All CompetitorsInsiders & InstitutionsBML Capital Management LLCSold 554,362 shares on 4/23/2024Ownership: 2.348%Mirador Capital Partners LPBought 20,660 shares on 4/18/2024Ownership: 0.054%Perceptive Advisors LLCBought 605,686 shares on 2/26/2024Ownership: 14.096%Forefront Analytics LLCBought 8,955 shares on 2/15/2024Ownership: 0.078%Private Advisor Group LLCBought 12,975 shares on 2/6/2024Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions ATHA Stock Analysis - Frequently Asked Questions Should I buy or sell Athira Pharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHA shares. View ATHA analyst ratings or view top-rated stocks. What is Athira Pharma's stock price target for 2024? 1 equities research analysts have issued 12 month price objectives for Athira Pharma's shares. Their ATHA share price targets range from $5.00 to $19.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 497.0% from the stock's current price. View analysts price targets for ATHA or view top-rated stocks among Wall Street analysts. How have ATHA shares performed in 2024? Athira Pharma's stock was trading at $2.43 at the beginning of the year. Since then, ATHA stock has decreased by 17.3% and is now trading at $2.01. View the best growth stocks for 2024 here. When is Athira Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ATHA earnings forecast. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) issued its earnings results on Thursday, February, 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.96) by $0.25. What ETF holds Athira Pharma's stock? Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 3.87% of its portfolio. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR). When did Athira Pharma IPO? Athira Pharma (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager. Who are Athira Pharma's major shareholders? Athira Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (2.35%) and Mirador Capital Partners LP (0.05%). Insiders that own company stock include Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington. View institutional ownership trends. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATHA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
